TCF7L1 and prostate adenocarcinoma: In order to evaluate the contribution of WNT4/TCF7L1 to the malignant progression of human prostate adenocarcinomas, AR-positive C4-2 and LNCaP cells stably expressing TCF7L1 were treated with the WNT4 protein.